Gadolinium deposition in the brain: Do we know enough to change practice?

Radiology

Volumn 279, Issue 1, 2016, Pages 323-324

  Reeder, Scott B ^a   Gulani, Vikas ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; CONTRAST MEDIUM;

BRAIN TISSUE; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG RETENTION; DRUG SAFETY; HEALTH HAZARD; HUMAN; KIDNEY FAILURE; LETTER; MEDICAL DECISION MAKING; MEDICAL INFORMATION; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; RELIABILITY; RISK ASSESSMENT; BRAIN; NUCLEAR MAGNETIC RESONANCE IMAGING;

BRAIN; CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 84962878071     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2016151372     Document Type: Letter

References (3)

1. Radbruch A, Weberling LD, Kieslich PJ, et al. Gadolinium retention in the dentate nucleus and globus pallidus is dependent on the class of contrast agent. Radiology 2015; 275(3):783-791.
2. Kanal E, Tweedle MF. Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology 2015; 275(3):630-634.
3. Kanda T, Osawa M, Oba H, et al. High signal intensity in dentate nucleus on unenhanced T1-weighted MR images: association with linear versus macrocyclic gadolinium chelate administration. Radiology 2015;275(3):803-809.